Literature DB >> 25174501

Editorial: The Innovative Medicines Initiative--collaborations are key to innovating R&D processes.

Hugh Laverty1, Michel Goldman.   

Abstract

Mesh：

Year:  2014        PMID： 25174501     DOI： 10.1002/biot.201400487

Source DB:  PubMed          Journal:  Biotechnol J        ISSN： 1860-6768            Impact factor:   4.677


× No keyword cloud information.
  5 in total

1.  Preclinical research strategies for newly approved drugs as reflected in early publication patterns.

Authors:  Ursula Köster; Ingo Nolte; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-11-26       Impact factor: 3.000

2.  Expectations and satisfaction of academic investigators in nonclinical collaboration with the pharmaceutical industry.

Authors:  Marjan Amiri; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-02-28       Impact factor: 3.000

3.  Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencing-Based Oncology Assays.

Authors:  Jason D Merker; Kelly Devereaux; A John Iafrate; Suzanne Kamel-Reid; Annette S Kim; Joel T Moncur; Stephen B Montgomery; Rakesh Nagarajan; Bryce P Portier; Mark J Routbort; Craig Smail; Lea F Surrey; Patricia Vasalos; Alexander J Lazar; Neal I Lindeman
Journal:  Arch Pathol Lab Med       Date:  2018-10-30       Impact factor: 5.534

Review 4.  Opportunities and Challenges for Drug Development: Public-Private Partnerships, Adaptive Designs and Big Data.

Authors:  Oktay Yildirim; Matthias Gottwald; Peter Schüler; Martin C Michel
Journal:  Front Pharmacol       Date:  2016-12-06       Impact factor: 5.810

Review 5.  The Innovative Medicines Initiative -10 Years of Public-Private Collaboration.

Authors:  Hugh Laverty; Pierre Meulien
Journal:  Front Med (Lausanne)       Date:  2019-12-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.